Allarity Therapeutics(ALLR) - 2024 Q4 - Annual Results

Exhibit 99.1 Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 - Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025 - Enrollment in new Phase 2 SCLC trial to begin in Q2-Q3 2025, fully funded by ...